Simpson Thacher represented Athenex Inc. (“Athenex”) in connection with its follow-on offering of 4,300,000 shares of common stock. The offering raised US$65.6 million of gross proceeds before exercise of the greenshoe. Deutsche Bank and RBC Capital Markets acted as joint bookrunning managers of the offering and as representatives for the underwriters of the offering.

Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Athenex’s common stock is traded on the NASDAQ Global Select Market under the symbol “ATNX.”

The Simpson Thacher team for the transaction included Chris Lin, Daniel Fertig, Brian Mathes and Andrew Laub (Corporate); Noah Leibowitz, Jeffrey Ostrow and Amber Harezlak (Intellectual Property); Katherine Helm (FDA Regulatory); and Rob Holo and Pierce Pandolph (Tax).